Journal article icon

Journal article

Efficacy and safety of monotherapy with sirukumab compared to adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Abstract:

Objective

This randomised, double-blind, parallel-group, phase 3 study compared monotherapy with sirukumab, an antiinterleukin-6 cytokine monoclonal antibody, to adalimumab monotherapy in patients with rheumatoid arthritis (RA).

Methods

Biologic-naïve patients with active RA who were inadequate responders or were intolerant to, or inappropriate for, methotrexate were randomised to subcutaneous sirukumab 100 mg every 2 weeks (q2w; n=187), sirukumab 50 mg every 4 w...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1136/annrheumdis-2017-212496

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Oxford college:
St Peters College
Expand authors...
Janssen Research and Development More from this funder
GlaxoSmithKline More from this funder
Publisher:
BMJ Publishing Group Publisher's website
Journal:
Annals of the Rheumatic Diseases Journal website
Volume:
77
Issue:
5
Pages:
658-666
Publication date:
2018-02-26
Acceptance date:
2018-01-09
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
Pubs id:
pubs:819910
URN:
uri:7d169b40-19d0-45e2-9ba2-5e01976b19e8
UUID:
uuid:7d169b40-19d0-45e2-9ba2-5e01976b19e8
Local pid:
pubs:819910

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP